TNFSF13B and irritable bowel syndrome: The anti-BAFF monoclonal antibody effectively reduced BAFF levels in vivo and in vitro and improved body weight loss, DAI score, colon length, spleen weight and colonic pathological damage in DSS-induced colitis mice, suggesting that BAFF blockade is effective against IBD.